S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
Fraud Expert: Dump these three popular stocks (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
Fraud Expert: Dump these three popular stocks (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
Fraud Expert: Dump these three popular stocks (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
Fraud Expert: Dump these three popular stocks (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
Fraud Expert: Dump these three popular stocks (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
Fraud Expert: Dump these three popular stocks (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
Fraud Expert: Dump these three popular stocks (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
Fraud Expert: Dump these three popular stocks (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
NASDAQ:AFMD

Affimed (AFMD) Stock Forecast, Price & News

$0.46
-0.01 (-2.11%)
(As of 09/26/2023 ET)
Compare
Today's Range
$0.45
$0.49
50-Day Range
$0.46
$0.63
52-Week Range
$0.45
$2.55
Volume
403,034 shs
Average Volume
958,926 shs
Market Capitalization
$69.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Affimed MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
1,086.4% Upside
$5.50 Price Target
Short Interest
Healthy
1.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.95
Upright™ Environmental Score
News Sentiment
0.27mentions of Affimed in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.85) to ($0.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

418th out of 964 stocks

Biotechnology Industry

13th out of 26 stocks


AFMD stock logo

About Affimed (NASDAQ:AFMD) Stock

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

AFMD Price History

AFMD Stock News Headlines

Affimed (NASDAQ:AFMD) Coverage Initiated by Analysts at StockNews.com
Affimed (NASDAQ:AFMD) Given "Overweight" Rating at Cantor Fitzgerald
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
What 6 Analyst Ratings Have To Say About Affimed
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Expert Ratings for Affimed
Affimed N.V.
Where Affimed Stands With Analysts
Affimed (AFMD) Gets a Buy from H.C. Wainwright
Affimed Q2 2023 Earnings Preview
See More Headlines
Receive AFMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter.

AFMD Company Calendar

Last Earnings
8/10/2023
Today
9/27/2023
Next Earnings (Estimated)
11/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AFMD
Employees
219
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.50
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+1,086.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-90,610,000.00
Net Margins
-357.49%
Pretax Margin
-359.20%

Debt

Sales & Book Value

Annual Sales
$43.58 million
Book Value
$1.31 per share

Miscellaneous

Free Float
143,664,000
Market Cap
$69.23 million
Optionable
Optionable
Beta
2.11
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Adi Hoess M.D. (Age 62)
    Ph.D., CEO, MD & Member of Management Board
    Comp: $815.34k
  • Mr. Angus W. Smith (Age 41)
    CFO & Member of Management Board
    Comp: $671.27k
  • Dr. Wolfgang Fischer (Age 59)
    MD, COO & Member of Management Board
    Comp: $636.05k
  • Ms. Denise Mueller (Age 53)
    Chief Bus. Officer & Member of Management Board
    Comp: $618.98k
  • Dr. Andreas Harstrick M.D. (Age 62)
    Chief Medical Officer & Member of Management Board
    Comp: $527.2k
  • Dr. Arndt Justus Georg Schottelius M.D. (Age 57)
    Ph.D., Chief Scientific Officer & Member of Management Board
    Comp: $639.25k
  • Prof. Melvyn Little
    Founder & Consultant
  • Mr. Michael Wolf (Age 56)
    Head of Fin. & Admin.
  • Mr. Alexander Fudukidis
    Head of Investor Relations & Director of Investor Relations
  • Mary Beth Sandin
    VP of Marketing & Communications













AFMD Stock - Frequently Asked Questions

Should I buy or sell Affimed stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AFMD shares.
View AFMD analyst ratings
or view top-rated stocks.

What is Affimed's stock price forecast for 2023?

8 Wall Street research analysts have issued 12 month price objectives for Affimed's shares. Their AFMD share price forecasts range from $1.00 to $7.00. On average, they predict the company's share price to reach $5.50 in the next year. This suggests a possible upside of 1,086.4% from the stock's current price.
View analysts price targets for AFMD
or view top-rated stocks among Wall Street analysts.

How have AFMD shares performed in 2023?

Affimed's stock was trading at $1.24 at the start of the year. Since then, AFMD shares have decreased by 62.6% and is now trading at $0.4636.
View the best growth stocks for 2023 here
.

When is Affimed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023.
View our AFMD earnings forecast
.

How were Affimed's earnings last quarter?

Affimed (NASDAQ:AFMD) released its quarterly earnings data on Thursday, August, 10th. The biopharmaceutical company reported ($0.22) EPS for the quarter, meeting analysts' consensus estimates of ($0.22). The biopharmaceutical company earned $1.51 million during the quarter, compared to analyst estimates of $4.83 million. Affimed had a negative trailing twelve-month return on equity of 79.96% and a negative net margin of 357.49%.

What other stocks do shareholders of Affimed own?
What is Affimed's stock symbol?

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

Who are Affimed's major shareholders?

Affimed's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.82%), Renaissance Technologies LLC (0.39%), State Street Corp (0.38%), BNP Paribas Arbitrage SNC (0.35%), Intellectus Partners LLC (0.28%) and Goldman Sachs Group Inc. (0.21%).

How do I buy shares of Affimed?

Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Affimed's stock price today?

One share of AFMD stock can currently be purchased for approximately $0.46.

How much money does Affimed make?

Affimed (NASDAQ:AFMD) has a market capitalization of $69.23 million and generates $43.58 million in revenue each year. The biopharmaceutical company earns $-90,610,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.

How many employees does Affimed have?

The company employs 219 workers across the globe.

How can I contact Affimed?

Affimed's mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The official website for the company is www.affimed.com. The biopharmaceutical company can be reached via phone at 496221674360, via email at ir@affimed.com, or via fax at 49-6221-653-0777.

This page (NASDAQ:AFMD) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -